Standards; Chiral Molecules; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
Boiling Point:
N/A
应用:
Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
危险品信息:
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
您的位置：
